A lower court erred in nixing Smith & Nephew's $85 million win over Arthrex in a patent dispute, the U.S. Court of Appeals for the Federal Circuit decided yesterday.

The latest turn in a nearly decade-long legal battle between Smith & Nephew (FTSE:SN, NYSE:SNN) and Arthrex over surgical anchor patents swung Smith & Nephew's way yesterday, when the U.S. Court of Appeals for the Federal Circuit overturned a lower court's ruling and sent the case back for reconsideration.
The British orthopedic medical device company first sued Arthrex in 2004 for patent infringement over anchors used in shoulder repair surgery. SNN won $20.5 million in a June 2008 ruling that Arthrex willfully infringed the patents. After the appeals court overturned that decision in November 2009, the case went back to trial with a new interpretation of the terms of the patent.
A jury granted SNN an $85 million win in June 2011, finding that Arthrex was guilty of patent infringement with its SutureTak, PushLock and Bio-PushLock shoulder repair anchors.
But in December 2011, an Oregon judge ruled that Arthrex didn't infringe on SNN's surgical anchor patents, finding that "no reasonable jury could possibly find that Arthrex infringed in this case," including via indirect infringement.
Boston Scientific denies allegations by stents rival OrbusNeich that it tried to block the seizure of...
Hologic wins FDA approval for its new C-View 2D imaging software for use with its 3D breast...
The hallowed emerging markets in Brazil, Russia, India and China aren't generating the kind of growth...
Medical device company Bausch + Lomb won FDA approval for its Trulign Toric intraocular lens, the 1st...
California medical device maker Claret Medical's embolic protection technology captures debris...